ClinicalCodes.org

An online clinical codes repository to improve validity and reproducibility of medical database research

Research article:

HbA1C variability and hypoglycemia hospitalization in adults with type 1 and type 2 diabetes: a nested case-control study

Reference:

Victor W. Zhong; Juhaeri Juhaeri; Stephen R. Cole; Christina M. Shay; Penny Gordon-Larsen; Evangelos Kontopantelis; Elizabeth J Mayer-Davis(2017) HbA1C variability and hypoglycemia hospitalization in adults with type 1 and type 2 diabetes: a nested case-control study. Journal of Diabetes and its Complications, doi: http://dx.doi.org/10.1016/j.jdiacomp.2017.10.008

Link to article
http://www.jdcjournal.com/article/S1056-8727(17)31226-6/fulltext
Abstract
Aims: To determine association between HbA1C variability and hypoglycemia requiring hospitalization (HH) in adults with type 1 diabetes (T1D) and type 2 diabetes (T2D). Methods: Using nested case-control design in electronic health record data in England, one case with first or recurrent HH was matched to one control who had not experienced HH in incident T1D and T2D adults. HbA1C variability was determined by standard deviation of ≥3 HbA1C results. Conditional logistic models were applied to determine association of HbA1C variability with first and recurrent HH. Results: In T1D, every 1.0% increase in HbA1C variability was associated with 90% higher first HH risk (95% CI, 1.25-2.89) and 392% higher recurrent HH risk (95% CI, 1.17- 20.61). In T2D, a 1.0% increase in HbA1C variability was associated with 556% higher first HH risk (95% CI, 3.88-11.08) and 573% higher recurrent HH risk (95% CI, 1.59-28.51). In T2D for first HH, the association was the strongest in non-insulin non-sulfonylurea users (P<0.0001); for recurrent HH, the association was stronger in insulin users than sulfonylurea users (P=0.07). The HbA1C variability-HH association was stronger in more recent years in T2D (P≤0.004). Conclusions: HbA1C variability is a strong predictor for HH in T1D and T2D.
Author for correspondence
Elizabeth J Mayer-Davis
Email for correspondence
mayerdav@email.unc.edu

Clinical code lists:

Click to view and download

Code list
Res50: type 1 diabetes Download this codelist
Res50: type 2 diabetes Download this codelist
Res50: AIDS Download this codelist
Res50: Metastatic tumour Download this codelist
Res50: Moderate or severe liver disease Download this codelist
Res50: cancer Download this codelist
Res50: diabetic complications Download this codelist
Res50: hemiplegia and paraplegia Download this codelist
Res50: renal disease Download this codelist
Res50: stroke Download this codelist
Res50: chronic pulmonary disease Download this codelist
Res50: congestive heart disease Download this codelist
Res50: dementia Download this codelist
Res50: mild liver disease Download this codelist
Res50: peptic ulcer disease Download this codelist
Res50: myocardial infarction Download this codelist
Res50: peripheral vascular disease Download this codelist
Res50: rheumatological disease Download this codelist
Res50: diseases causing hypoglycemia Download this codelist
Res50: insulin Download this codelist
Res50: metformin Download this codelist
Res50: sulfonylureas Download this codelist
Res50: glinide Download this codelist
Res50: thiazolidinediones Download this codelist
Res50: DPP-4 inhibitors Download this codelist
Res50: GLP-1 receptor agonists Download this codelist
Res50: acarbose Download this codelist
Res50: SGLT-2 inhibitors Download this codelist
Res50: alpha-blockers Download this codelist
Res50: beta-blockers Download this codelist
Res50: calcium blockers Download this codelist
Res50: diuretics Download this codelist
Res50: nitrates Download this codelist
Res50: RAS inhibitors Download this codelist

0 comments have been posted.

Please log in to leave a comment.